Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (hepatocytes) | 0.10 |
| chemistry Open Targets | compounds already reach it: fomepizole, nitrefazole | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 117 | 0.91 |
| pathways Reactome | 3 pathways; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 7367
Sealed predictions
- ADH1A in dopamine neurons, braak+0.85 (p 0.004) → +0.05 (p 0.894)receipt 7374
Swarm cases
receipt 7374: ADH1A in dopamine neurons, braak
- power
- full sample +0.56 (p 0.015, n 18), 95% CI +0.13 to +0.82. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.60 (p 0.0086, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.56 (p 0.017, n 18). not the mix.
- skeptic
- leave-one-out range +0.51 to +0.70, sign flips 0; without severely affected donors +0.56 (p 0.015, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ADH1A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts